Immunologiya最新文献

英文中文

Changes in the functional properties of dendritic cells upon contact with microorganisms of the genera Bacillus, Lactiplantibacillus and Limosilactobacillus 树突状细胞与芽孢杆菌属、乳酸杆菌属和乳酸杆菌属微生物接触后功能特性的变化

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-5-504-514

V. Talayev, I. Zaichenko, M. Svetlova, E. Voronina, O. Babaykina, I. Soloveva, I. Belova, A. G. Tochilina

引用次数: 0

Сontroversial role of innate immunity factors in impaired fertility in men affected by varicocele Сontroversial先天免疫因素在精索静脉曲张男性生育能力受损中的作用

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-1-61-70

E. Khasanova, L. Gankovskaya, V. Grechenko

引用次数: 0

Development of criteria for immobilization of human erythrocytes of phenotypes R1R1 and R2R2 on the solid phase in determining the content of anti-D-antibodies IgG in immunoglobulin human antirhesus Rho(D) preparations by enzyme immunoassay 建立了用酶免疫分析法测定人抗恒河Rho(D)免疫球蛋白制剂中抗D抗体IgG含量时，R1R1和R2R2型人红细胞固相固定标准

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-2-208-216

E. Shvedova, S. A. Leshina, D. S. Davydov, I. Borisevich, E. Kudasheva

引用次数: 1

The proteins of γ-globulin fraction, that bind metal ions, in physiological immune regulation. Polarization of the responses and rational limitation of inflammation γ-球蛋白部分蛋白，结合金属离子，在生理免疫调节中起作用。炎症反应的极化与合理限制

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-4-468-476

S. B. Cheknev

引用次数: 0

Reprogramming of myeloid cells of the tumor microenvironment increases the efficiency of CTLA-4 and PD-1 blockade in experimental malignant melanoma immunotherapy 肿瘤微环境髓系细胞重编程提高CTLA-4和PD-1阻断在实验性恶性黑色素瘤免疫治疗中的效率

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-6-673-690

A. Pichugin, S.A. Podsvirova, E. Ushakova, D.M. Spirin, E. Lebedeva, R. Ataullakhanov

引用次数: 0

Dynamics of specific humoral response in COVID-19 patients COVID-19患者特异性体液反应动态

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-1-71-77

V. Zakurskaya, L. Sizyakina, M. Kharitonova, S. Shlyk

Introduction. The pandemic caused by the SARS-CoV-2 virus is an important medical and social problem. It remains unclear the stability of the developed humoral immunity against the SARS-CoV-2 virus, the average duration of preservation of the titer of specific antibodies. The need to identify humoral mechanisms of immune defense in patients with COVID-19 determined the purpose of this study. The aim of the study – to evaluate the dynamics of changes in the content of specific IgG antibodies against various antigens of the SARS-CoV-2 virus and B-lymphocyte subpopulations throughout the year in people who have had COVID-19. Material and methods. The study included 90 patients who had undergone COVID-19 in various forms, subsequently divided into 2 groups: persons with asymptomatic and mild course (57 patients) and with moderate or severe course of the disease (33 patients). The dynamics of the concentration of specific antibodies to the SARS-CoV-2 virus was evaluated by enzyme immunoassay every 3 months for a year. The content of the total pool B-lymphocytes (naive B-lymphocytes, memory B-cells, regulatory B-lymphocytes) and various subpopulations was evaluated by flow cytofluorimetry. Results. When assessing the dynamics of IgG to the S-protein of the SARS-CoV-2 virus, their preservation was noted by the 12th month after recovery. In patients with severe and moderate COVID-19 forms, these indicators are significantly higher. More severe forms of COVID-19 are accompanied by significantly higher content level of memory B cells throughout the observation period. Conclusion. Moderate and severe forms of COVID-19 induce more persistent postinfectious humoral immunity, provided by an increase in memory B cells in comparison with lighter forms.

介绍。由SARS-CoV-2病毒引起的大流行是一个重要的医学和社会问题。目前尚不清楚针对SARS-CoV-2病毒的体液免疫的稳定性，特异性抗体滴度的平均保存时间。确定COVID-19患者免疫防御的体液机制的需要决定了本研究的目的。该研究的目的是评估COVID-19患者全年针对SARS-CoV-2病毒各种抗原和b淋巴细胞亚群的特异性IgG抗体含量变化的动态。材料和方法。该研究纳入了90例不同形式的COVID-19患者，随后分为两组:无症状和轻度患者(57例)和中重度疾病患者(33例)。每隔3个月用酶免疫法测定1年内SARS-CoV-2病毒特异性抗体的浓度动态变化。流式细胞荧光法测定总池b淋巴细胞(幼稚b淋巴细胞、记忆b淋巴细胞、调节性b淋巴细胞)和各亚群的含量。结果。当评估IgG对SARS-CoV-2病毒s蛋白的动态变化时，在恢复后12个月，它们的保存被注意到。在重症和中度COVID-19患者中，这些指标明显更高。在整个观察期间，更严重的COVID-19形式伴随着显著更高的记忆B细胞含量水平。结论。与轻度形式相比，中度和重度形式的COVID-19通过增加记忆B细胞提供更持久的感染后体液免疫。

{"title":"Dynamics of specific humoral response in COVID-19 patients","authors":"V. Zakurskaya, L. Sizyakina, M. Kharitonova, S. Shlyk","doi":"10.33029/0206-4952-2022-43-1-71-77","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-1-71-77","url":null,"abstract":"Introduction. The pandemic caused by the SARS-CoV-2 virus is an important medical and social problem. It remains unclear the stability of the developed humoral immunity against the SARS-CoV-2 virus, the average duration of preservation of the titer of specific antibodies. The need to identify humoral mechanisms of immune defense in patients with COVID-19 determined the purpose of this study. The aim of the study – to evaluate the dynamics of changes in the content of specific IgG antibodies against various antigens of the SARS-CoV-2 virus and B-lymphocyte subpopulations throughout the year in people who have had COVID-19. Material and methods. The study included 90 patients who had undergone COVID-19 in various forms, subsequently divided into 2 groups: persons with asymptomatic and mild course (57 patients) and with moderate or severe course of the disease (33 patients). The dynamics of the concentration of specific antibodies to the SARS-CoV-2 virus was evaluated by enzyme immunoassay every 3 months for a year. The content of the total pool B-lymphocytes (naive B-lymphocytes, memory B-cells, regulatory B-lymphocytes) and various subpopulations was evaluated by flow cytofluorimetry. Results. When assessing the dynamics of IgG to the S-protein of the SARS-CoV-2 virus, their preservation was noted by the 12th month after recovery. In patients with severe and moderate COVID-19 forms, these indicators are significantly higher. More severe forms of COVID-19 are accompanied by significantly higher content level of memory B cells throughout the observation period. Conclusion. Moderate and severe forms of COVID-19 induce more persistent postinfectious humoral immunity, provided by an increase in memory B cells in comparison with lighter forms.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Peripheral blood B-lymphocyte subpopulations coexpressing CD5 and chemokine receptors in patients with chronic obstructive pulmonary disease 慢性阻塞性肺疾病患者外周血b淋巴细胞亚群共表达CD5和趋化因子受体

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-2-197-207

A. Kadushkin, A. Tahanovich, L. Movchan, M. Zafranskaya, V. Dziadzichkina, T. Shman

引用次数: 1

Phenotypic and functional characteristic analysis of THP-1 cell line as a model of inflammation THP-1细胞系作为炎症模型的表型和功能特征分析

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-3-277-287

E. Kokinos, D. Kuzmina, O. Kuchur, S. Tsymbal, V. A. Vasilichin, A. V. Galochkina, A.V. Zavirskyi, V. Basharin, A. Shtro, A. Shtil, M. Dukhinova

引用次数: 0

Features of postinfectious immunity formation in a patient with common variable immune deficiency and severe COVID-19 course: a description of a clinical case 共同可变免疫缺陷伴重症COVID-19病程的患者感染后免疫形成特征:临床病例描述

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-4-440-446

L. Sizyakina, I. Andreeva, N. Skripkina

Background. Common variable immune deficiency (CVID) is a complicating comorbid background of COVID-19. Post-infectious immunity formation to SARS-CoV-2 during a pandemic is of particular relevance for such patients. Aim of the study - to present the features of the development of postinfectious humoral immune response in a patient with CVID. Material and methods. Patient K., 49 years old, the diagnosis of CVID verified at the age of 33, has been receiving regular replacement therapy with intravenous immunoglobulins for the last 10 years. After intrafamily contact and infection with SARS-CoV-2 due to the progressive deterioration of the clinical course of COVID-19, he was admitted to a monoinfection hospital. Results. During the treatment of the severe clinical case of COVID-19 a patient with CVID proved to be effective therapy combining anti-cytokine drugs and additional courses of replacement therapy with intravenous immunoglobulins. 6 weeks later from the development of the clinic, the patient was detected specific antibodies to SARS-CoV-2 antigens - IgM (CP 4.73) and IgG (43 BAU), in 4 months the corresponding parameters were 3.55 (CP IgM) and 487 BAU (CP IgG). Comparative analysis of immunophenotyping of the patient's B lymphocytes before the disease, during periods of early and late convalescence showed the dynamics of changes in the number of naive B-lymphocytes, unswitched and switched B-memory cells, plasmablasts, B-reg and B-lymphocytes expressing intercellular cooperation molecules. Conclusion. In the patient with CVID the development of a specific humoral immune response to SARS-CoV-2 after a COVID-19 infection is accompanied by an increase in the proportion of B-memory cells, increased maturation of B-lymphocytes, coordinated dynamics of B-cell suppression and activation parameters. Copyright © 2022 Authors. All rights reserved.

背景。常见可变免疫缺陷(CVID)是COVID-19复杂的共病背景。在大流行期间，对SARS-CoV-2的感染后免疫形成对这些患者特别重要。本研究的目的-介绍CVID患者感染后体液免疫反应的发展特点。材料和方法。患者K.， 49岁，33岁确诊为CVID，过去10年一直接受静脉注射免疫球蛋白的常规替代治疗。由于COVID-19临床病程的进行性恶化，家庭内接触并感染SARS-CoV-2后，被送入单感染医院。结果。在COVID-19重症临床病例的治疗过程中，1例CVID患者被证明是有效的治疗方法，联合抗细胞因子药物和额外的静脉注射免疫球蛋白替代治疗。临床发展6周后，患者检测到SARS-CoV-2抗原特异性抗体- IgM (CP 4.73)和IgG (43 BAU)， 4个月时相应参数分别为3.55 (CP IgM)和487 BAU (CP IgG)。对比分析患者在发病前、恢复期早期和晚期的B淋巴细胞免疫表型，可以发现初始B淋巴细胞、未开关和开关的B记忆细胞、质母细胞、表达细胞间合作分子的B-reg和B淋巴细胞数量的动态变化。结论。在CVID患者中，COVID-19感染后对SARS-CoV-2的特异性体液免疫反应的发展伴随着b记忆细胞比例的增加、b淋巴细胞成熟的增加、b细胞抑制和激活参数的协调动力学。版权所有©2022作者。版权所有。

{"title":"Features of postinfectious immunity formation in a patient with common variable immune deficiency and severe COVID-19 course: a description of a clinical case","authors":"L. Sizyakina, I. Andreeva, N. Skripkina","doi":"10.33029/0206-4952-2022-43-4-440-446","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-4-440-446","url":null,"abstract":"Background. Common variable immune deficiency (CVID) is a complicating comorbid background of COVID-19. Post-infectious immunity formation to SARS-CoV-2 during a pandemic is of particular relevance for such patients. Aim of the study - to present the features of the development of postinfectious humoral immune response in a patient with CVID. Material and methods. Patient K., 49 years old, the diagnosis of CVID verified at the age of 33, has been receiving regular replacement therapy with intravenous immunoglobulins for the last 10 years. After intrafamily contact and infection with SARS-CoV-2 due to the progressive deterioration of the clinical course of COVID-19, he was admitted to a monoinfection hospital. Results. During the treatment of the severe clinical case of COVID-19 a patient with CVID proved to be effective therapy combining anti-cytokine drugs and additional courses of replacement therapy with intravenous immunoglobulins. 6 weeks later from the development of the clinic, the patient was detected specific antibodies to SARS-CoV-2 antigens - IgM (CP 4.73) and IgG (43 BAU), in 4 months the corresponding parameters were 3.55 (CP IgM) and 487 BAU (CP IgG). Comparative analysis of immunophenotyping of the patient's B lymphocytes before the disease, during periods of early and late convalescence showed the dynamics of changes in the number of naive B-lymphocytes, unswitched and switched B-memory cells, plasmablasts, B-reg and B-lymphocytes expressing intercellular cooperation molecules. Conclusion. In the patient with CVID the development of a specific humoral immune response to SARS-CoV-2 after a COVID-19 infection is accompanied by an increase in the proportion of B-memory cells, increased maturation of B-lymphocytes, coordinated dynamics of B-cell suppression and activation parameters. Copyright © 2022 Authors. All rights reserved.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19 基于血浆免疫球蛋白和单克隆抗体的药品治疗和预防COVID-19的疗效

Q4 Immunology and Microbiology

Immunologiya

Pub Date : 2022-01-01 DOI: 10.33029/0206-4952-2022-43-5-485-503

A. Soldatov, Z. Avdeeva, D. Gorenkov, L. M. Khantimirova, Yu.S. Paramonova, E.M. Smolina, V. Bondarev, V. A. Merkulov

The development of the COVID-19 pandemic initiated the search for effective drugs for the treatment and prevention of infection. Of particular importance for the fight against the pandemic is the timing of the introduction of drugs into clinical practice. Therefore, countries with developed healthcare systems (EU, USA, Russian Federation, etc.), issue conditional marketing authorizations of drugs for treatment and prevention of COVID-19, based on regulatory requirements for the circulation of medicines in emergency situations. The approval is issued on the basis of limited clinical data, with the condition that the full evaluation of safety and effectiveness will be carried out after the issuance of the authorization in the post-registration period. The COVID-19 pandemic has revolutionized the design and time frame of clinical trials, including phase I, II, and III adaptive trials, which has led to the approval of biologics for the treatment and prevention of COVID-19 in record time in most advanced pharmaceutical countries. At the same time, regulatory/healthcare authorities or international organizations constantly monitor the safety and effectiveness of used drugs and, if necessary, make adjustments (changes to the indications for use, dosage change, drug discontinuation etc.). Since the beginning of the pandemic, in fact, in conditions where the use of medicines was allowed based on very limited data, studies have begun to substantiate the safety and effectiveness of the use of immunoglobulin preparations and monoclonal antibodies for the treatment and prevention of COVID-19. As new data became available, changes were made regarding the indications for use, doses, and other characteristics of preparations of immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19. The review presents a critical analysis of the results of evaluation the safety and effectiveness of the use of immunoglobulin preparations and monoclonal antibodies in a pandemic. Copyright © 2022 Meditsina Publishers. All rights reserved.

COVID-19大流行的发展开启了寻找治疗和预防感染的有效药物的进程。在防治这一流行病的斗争中，特别重要的是将药物引入临床实践的时机。因此，医疗体系发达的国家(欧盟、美国、俄罗斯联邦等)根据紧急情况下药品流通的监管要求，发布了治疗和预防COVID-19药物的有条件上市许可。批准是在有限的临床数据基础上发出的，条件是在注册后期间授权发布后将进行充分的安全性和有效性评估。COVID-19大流行彻底改变了临床试验的设计和时间框架，包括I期、II期和III期适应性试验，这使得大多数先进制药国家以创纪录的时间批准了用于治疗和预防COVID-19的生物制剂。与此同时，监管/保健当局或国际组织不断监测使用药物的安全性和有效性，并在必要时进行调整(改变使用适应症、改变剂量、停药等)。事实上，自大流行开始以来，在允许根据非常有限的数据使用药物的情况下，研究已经开始证实使用免疫球蛋白制剂和单克隆抗体治疗和预防COVID-19的安全性和有效性。随着获得新数据，用于治疗和预防COVID-19的免疫球蛋白和单克隆抗体制剂的使用适应症、剂量和其他特性发生了变化。本综述对大流行期间使用免疫球蛋白制剂和单克隆抗体的安全性和有效性评价结果进行了批判性分析。版权所有©2022新浪传媒出版社。版权所有。

{"title":"The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19","authors":"A. Soldatov, Z. Avdeeva, D. Gorenkov, L. M. Khantimirova, Yu.S. Paramonova, E.M. Smolina, V. Bondarev, V. A. Merkulov","doi":"10.33029/0206-4952-2022-43-5-485-503","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-5-485-503","url":null,"abstract":"The development of the COVID-19 pandemic initiated the search for effective drugs for the treatment and prevention of infection. Of particular importance for the fight against the pandemic is the timing of the introduction of drugs into clinical practice. Therefore, countries with developed healthcare systems (EU, USA, Russian Federation, etc.), issue conditional marketing authorizations of drugs for treatment and prevention of COVID-19, based on regulatory requirements for the circulation of medicines in emergency situations. The approval is issued on the basis of limited clinical data, with the condition that the full evaluation of safety and effectiveness will be carried out after the issuance of the authorization in the post-registration period. The COVID-19 pandemic has revolutionized the design and time frame of clinical trials, including phase I, II, and III adaptive trials, which has led to the approval of biologics for the treatment and prevention of COVID-19 in record time in most advanced pharmaceutical countries. At the same time, regulatory/healthcare authorities or international organizations constantly monitor the safety and effectiveness of used drugs and, if necessary, make adjustments (changes to the indications for use, dosage change, drug discontinuation etc.). Since the beginning of the pandemic, in fact, in conditions where the use of medicines was allowed based on very limited data, studies have begun to substantiate the safety and effectiveness of the use of immunoglobulin preparations and monoclonal antibodies for the treatment and prevention of COVID-19. As new data became available, changes were made regarding the indications for use, doses, and other characteristics of preparations of immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19. The review presents a critical analysis of the results of evaluation the safety and effectiveness of the use of immunoglobulin preparations and monoclonal antibodies in a pandemic. Copyright © 2022 Meditsina Publishers. All rights reserved.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Immunologiya

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀